Topic: drug sales

Takeda's $585 million Chinese revenue for FY2017 was only one-tenth of what it collected from Japan, and buying Shire won't change that soon.

Tagrisso will enjoy quick uptake in a couple of new indications to win 95% of EGFR-mutated NSCLC patients by 2020, a bullish analyst figures.

GSK and Merck will still lead as the top vaccine makers in 2024, according to a new report, while Sanofi and Pfizer are expected to swap positions.

Many ASCO-watchers crowned Merck's Keytruda as king of the lung cancer market, but rivals Roche and BMS are kicking back.

Pfizer's Xalkori has picked up two FDA breakthrough designations, one for certain lung cancer patients and another in a rare form of lymphoma.  

Crestor sales nosedived by 42% to $389 million in Q1, well below analyst estimates, but execs hope new cancer drugs can cushion the fall.

Vermont lawmakers took it upon themselves to pass a bill allowing drug imports from Canada. The catch? It'll need an OK from the Trump administration.

Takeda expects Velcade sales to drop more than 30% this year, but it's hoping newer drugs Ninlanro and Entyvio help fill the gap.

What's notable about the 10 best-selling drugs over the past 25 years? Here's a hint: Today's king is passing, and the next has a long life ahead.

A strong euro doesn't explain away Bayer's consumer health stall—or the low turnout for key cancer meds Xofigo and Stivarga.